MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference - Seite 2

“I find the procedure in EAP to be quite straightforward” shared Dr. Alexander Schauwvlieghe, hematologist at AZ Sint-Jan Brugge AV Hospital in Belgium. “I'm a strong advocate for gut microbiome-based treatments, such as MaaT013, that prioritize immune restoration in GvHD. This approach helps maintain the patient's immune function, reducing the risk of infectious complications and relapse.”

A pivotal Phase 3 trial (n=75) evaluating MaaT013 (ARES trial - NCT04769895) in patients with corticosteroid and ruxolitinib-refractory gastrointestinal aGvHD is currently ongoing to confirm the results from the EAP. The Company previously shared the positive review by DSMB^[3] for the Phase 3 ARES trial, including a favorable benefit/risk ratio, with “high efficacy and low toxicity.”

Details of Oral Presentation at EBMT 2024

• Title: Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe
• Abstract number: OS13-07
• Session: OS13 Oral Session 13 | GVHD
• Session Date/Time: Wednesday, April 17, 10:30 – 11:45
• Location: Hall 5

About MaaT Pharma

MaaT Pharma, a leading clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma initiated an open-label, single-arm Phase 3 clinical trial in patients with acute GvHD, building on the positive results of its Phase 2 proof-of-concept. Its powerful discovery and analysis platform, gutPrint, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).